Arvinas Inc
ARVN7.530USD
+0.110+1.48%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
549.69MValor de mercado
PerdaP/L TTM
Mais detalhes de Arvinas Inc Empresa
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Informações da empresa
Código da empresaARVN
Nome da EmpresaArvinas Inc
Data de listagemSep 27, 2018
CEODr. John G. Houston, Ph.D.
Número de funcionários430
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 27
Endereço5 Science Park
CidadeNEW HAVEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal06511-1966
Telefone12035351456
Sitehttps://www.arvinas.com/
Código da empresaARVN
Data de listagemSep 27, 2018
CEODr. John G. Houston, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Detalhamento da receita
FY2025Q1
FY2024
FY2023
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
188.80M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 27 de jul
Atualizado em: dom, 27 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
Tipos de investidores
Investidores
Proporção
Investment Advisor
36.14%
Hedge Fund
24.67%
Investment Advisor/Hedge Fund
17.48%
Venture Capital
6.80%
Corporation
4.74%
Research Firm
3.41%
Individual Investor
2.23%
Sovereign Wealth Fund
1.70%
Pension Fund
0.37%
Other
2.45%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
503
71.52M
97.99%
-18.05M
2025Q1
525
68.48M
93.89%
-22.67M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
8.35M
11.44%
+1.30M
+18.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.04M
6.9%
-246.30K
-4.66%
Mar 31, 2025
Citadel Advisors LLC
3.88M
5.31%
+395.72K
+11.37%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.75M
5.14%
-273.88K
-6.81%
Mar 31, 2025
Pfizer Inc
3.46M
4.74%
--
--
Mar 31, 2025
RTW Investments L.P.
3.33M
4.57%
--
--
Mar 31, 2025
Logos Global Management LP
3.30M
4.52%
+3.30M
--
Jun 10, 2025
Opaleye Management Inc.
1.98M
2.71%
+350.00K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
1.90M
2.6%
+259.14K
+15.83%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.80M
2.47%
+1.80M
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
SPDR S&P Pharmaceuticals ETF
1.09%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.77%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Tema Oncology ETF
0.41%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares U.S. Pharmaceuticals ETF
0.25%
Zacks Small/Mid Cap ETF
0.18%
JPMorgan Fundamental Data Science Small Core ETF
0.15%
Tema Neuroscience and Mental Health ETF
0.15%
Ver Mais
SPDR S&P Pharmaceuticals ETF
Proporção1.09%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção0.77%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.46%
Tema Oncology ETF
Proporção0.41%
Federated Hermes MDT Small Cap Core ETF
Proporção0.3%
iShares U.S. Pharmaceuticals ETF
Proporção0.25%
Zacks Small/Mid Cap ETF
Proporção0.18%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.15%
Tema Neuroscience and Mental Health ETF
Proporção0.15%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
